# Efficacy and Safety of a PN Regimen Containing n-3 Fatty Acid in Patients Considered After GI Surgery

> **NCT00798447** · PHASE3 · COMPLETED · sponsor: **B. Braun Melsungen AG** · enrollment: 100 (estimated)

## Conditions studied

- GI Cancer

## Interventions

- **DRUG:** MLF 541
- **DRUG:** Lipofundin MCT

## Key facts

- **NCT ID:** NCT00798447
- **Lead sponsor:** B. Braun Melsungen AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2011-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00798447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00798447, "Efficacy and Safety of a PN Regimen Containing n-3 Fatty Acid in Patients Considered After GI Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00798447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*